Latest IPO in India: Positive Outlook for Accretion Pharmaceuticals Ltd – 7 Key Details You Need to Know
Latest IPO in India: Positive Outlook for Accretion Pharmaceuticals Ltd – 7 Key Details You Need to Know
Accretion Pharmaceuticals Ltd is launching its SME IPO on May 14, 2025. As one of the latest IPOs in India, this pharmaceutical company offers investors an exciting opportunity to enter the growing healthcare sector. Below, we break down all the essential IPO details including price band, subscription status, GMP, and more.
Company Overview
Founded in 2012, Accretion Pharmaceuticals Ltd is an Ahmedabad-based CDMO (Contract Development and Manufacturing Organization). It produces a broad range of pharmaceutical formulations such as tablets, capsules, ointments, lotions, oral liquids, medicated shampoos, and more. The company caters to both domestic and international markets and holds ISO 9001:2015, 14001:2015, and 22000:2018 certifications for its Sanand-based manufacturing unit.
IPO Timeline
- IPO Open Date: May 14, 2025
- IPO Close Date: May 16, 2025
- Basis of Allotment: May 19, 2025
- Refunds Initiated: May 20, 2025
- Shares Credited to Demat: May 20, 2025
- IPO Listing Date: May 21, 2025
IPO Price Band
The IPO price band is ₹96 to ₹101 per equity share, with a face value of ₹10 each. The issue price is expected to be finalized at ₹101.
Lot Size
- Lot Size: 1,200 shares
- Minimum Investment: ₹121,200
Key Dates
- Anchor Investor Bidding: May 13, 2025
- UPI Mandate Deadline: May 16, 2025, 5:00 PM IST
- Anchor Lock-in Ends (50%): June 18, 2025
- Anchor Lock-in Ends (Remaining 50%): August 17, 2025
Financials
| Particulars (₹ in Crores) | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue from Operations | 33.94 | 29.53 | 22.58 |
| EBITDA | 6.64 | 2.44 | 2.22 |
| Profit After Tax | 3.88 | 0.10 | 0.08 |
| Net Worth | 5.35 | 1.35 | 0.00 |
| Total Borrowings | 13.48 | 6.35 | 0.00 |
Strengths
- Diversified product range across dosage forms
- Experienced leadership team
- Quality-certified manufacturing unit
- Strong client portfolio in CDMO and loan licensing
Risks
- High dependence on Gujarat for domestic revenue (85%)
- Limited market share as an SME in a competitive sector
- Subject to strict regulatory oversight
IPO Anchor Investors Details
| Investor Category | Shares Offered | Percentage (%) |
|---|---|---|
| Anchor Investors | 2,11,680 | 7.19% |
| QIBs | 1,41,120 | 4.79% |
| NIIs | 12,22,800 | 41.51% |
| RIIs | 12,22,800 | 41.51% |
| Market Maker | 1,47,600 | 5.00% |
IPO Promoter Holding Details
| Promoter | Designation | Pre-Issue Holding (%) | Post-Issue Holding (%) |
|---|---|---|---|
| Mr. Vivek Ashok Kumar Patel | Managing Director | 100.00% | 73.14% |
| Mr. Harshad Nanubhai Rathod | Executive Director & CFO | — | — |
| Mr. Mayur Popatlal Sojitra | Executive Director | — | — |
| Mr. Hardik Mukundbhai Prajapati | Executive Director | — | — |
IPO Grey Market Premium (GMP)
| Date | GMP (₹) |
|---|---|
| May 11, 2025 | ₹0 |
Note: As of May 11, 2025, there is no active grey market premium for Accretion Pharmaceuticals Ltd IPO.
Final Thoughts
Accretion Pharmaceuticals Ltd’s IPO provides a promising entry into India’s growing pharma manufacturing space. The company’s solid financials and certifications are positives, but geographical dependence and regulatory risks need to be considered. As always, investors should conduct thorough research or consult financial experts before investing.